http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108992666-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2018-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108992666-B |
| titleOfInvention | Cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant of targeting co-carried antigen and TLR agonist, preparation method and application |
| abstract | The invention relates to a cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant targeting a co-carried antigen and a TLR agonist, a preparation method and application thereof, wherein the vaccine adjuvant is characterized in that a hydrophobic inner core is coated with the TLR7 agonist, a phospholipid layer is coated with the TLR4 agonist, the antigen is adsorbed by cationic phospholipid in the phospholipid layer, and meanwhile, the cationic phospholipid in the phospholipid layer is connected with mannose ligand so that the cationic phospholipid-polymer hybrid nanoparticle vaccine adjuvant has the capability of specifically targeting antigen presenting cell dendritic cells, thereby enhancing the uptake and maturation promotion effects on DC cells; the antigen is protected by the hybrid nanoparticles, the antigen uptake of DC cells is improved, the immune response after antigen stimulation is obviously enhanced by the TLR agonist, the cross presentation of the antigen is obviously improved, the powerful T cell killing effect is generated, the secretion of cell factors is induced, the long-acting memory T cell reaction is generated, and the anti-tumor effect has better prevention capability on tumors. |
| priorityDate | 2018-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.